“

Kasia’s strategy is one that may help to get over the hump that has been classically bedeviling biomedical people in the U.S. to move something from the bench to the field without quite so many hurdles, the real-world [vaccine] application of this could potentially really have an impact, then I start daydreaming about other possibilities and if you can somehow add to the treatment of cancer or any other disease, adapting your technology in immunotherapies.